How we respond both now and going forward will help mitigate the impact of COVID-19, and to the extent possible preserve children’s rights to Survive, Learn, and Be Protected. We will focus our efforts on the most critical work essential to maintaining these commitments to the extent possible.
Antimicrobial resistance (AMR) has become a global public health concern and Lebanon is of no exception to this issue. The spread of antimicrobial-resistant bacteria is considered an alarming public health threat, with a potential extent similar to global warming and other social and environmental t...hreats.
more
Interium guidance, 25 June 2021Timely and accurate diagnostic testing is an essential tool in preventing and controlling the spread of COVID-19. This document describes recommendations for national testing strategies and the use of PCR and rapid antigen tests in different transmission scenarios of t...he COVID-19 outbreak, including how testing might be rationalized in low resource settings. All testing should be followed by a strong public health response including isolating those who test positive and providing them care, contact tracing and quarantine of contacts.
more
The humanitarian crisis in Yemen is the worst in the world, with over 80 per cent of the population estimated to be in need of humanitarian assistance. The protracted crisis has displaced millions of Yemenis, placing pressure on host communities with limited capacity to support displaced populations....
more
Immunization is one of the most cost-effective public health interventions to date, saving an estimated 2 to 3 million lives each year. As a direct result of immunization, the world is closer than ever to eradicating polio, and deaths from measles – a major child killer – have declined by 73 per... cent worldwide between 2000 and 2018, saving an estimated 23.2 million children’s lives. The emergence of COVID-19, however, threatens to reverse this progress by severely limiting access to life-saving vaccines.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
What near-term climate impacts should worry us most?
Supporting the most exposed and vulnerable societies to reduce
regional and global climate risks
CHILD AND ADOLESCENT HEALTH IN THE WHO EUROPEAN REGION:
ADOLESCENT MENTAL HEALTH FACT SHEET